WO2002055100A3 - Method and composition for inhibition of tumor growth and enhancing an immune response - Google Patents

Method and composition for inhibition of tumor growth and enhancing an immune response Download PDF

Info

Publication number
WO2002055100A3
WO2002055100A3 PCT/US2001/051339 US0151339W WO02055100A3 WO 2002055100 A3 WO2002055100 A3 WO 2002055100A3 US 0151339 W US0151339 W US 0151339W WO 02055100 A3 WO02055100 A3 WO 02055100A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhancing
composition
immune response
inhibition
tumor growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/051339
Other languages
French (fr)
Other versions
WO2002055100A9 (en
WO2002055100A2 (en
Inventor
Jay A Berzofsky
Masaki Terabe
Debra D Donaldson
So Matsui
Nancy Noben-Trauth
William E Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
US Department of Health and Human Services
Original Assignee
Genetics Institute LLC
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26981351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002055100(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC, US Department of Health and Human Services filed Critical Genetics Institute LLC
Priority to DE60135481T priority Critical patent/DE60135481D1/en
Priority to JP2002555834A priority patent/JP2004537500A/en
Priority to AU2002243443A priority patent/AU2002243443A1/en
Priority to EP01989341A priority patent/EP1333850B1/en
Priority to DK01989341T priority patent/DK1333850T3/en
Publication of WO2002055100A2 publication Critical patent/WO2002055100A2/en
Publication of WO2002055100A3 publication Critical patent/WO2002055100A3/en
Anticipated expiration legal-status Critical
Publication of WO2002055100A9 publication Critical patent/WO2002055100A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided is a method and composition for enhancing an immune response in a subject by administering to the subject an inhibitor of IL-13 or an inhibitor of an NK-T cell to the subject. The method can be used to prevent growth of a tumor in the subject, e.g., to inhibit tumor recurrence or metastasis. The method can also be used to enhance a response to a vaccine in a subject.
PCT/US2001/051339 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response Ceased WO2002055100A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60135481T DE60135481D1 (en) 2000-10-20 2001-10-22 USE OF IL-13 INHIBITORS FOR THE TREATMENT OF TUMORS
JP2002555834A JP2004537500A (en) 2000-10-20 2001-10-22 Methods and compositions for inhibiting tumor growth and enhancing immune response
AU2002243443A AU2002243443A1 (en) 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response
EP01989341A EP1333850B1 (en) 2000-10-20 2001-10-22 Use of il-13 inhibitors for the treatment of tumors
DK01989341T DK1333850T3 (en) 2000-10-20 2001-10-22 Use of IL-13 Inhibitors to Treat Tumors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69360000A 2000-10-20 2000-10-20
US09/693,600 2000-10-20
US31818501P 2001-09-07 2001-09-07
US60/318,185 2001-09-07

Publications (3)

Publication Number Publication Date
WO2002055100A2 WO2002055100A2 (en) 2002-07-18
WO2002055100A3 true WO2002055100A3 (en) 2003-03-27
WO2002055100A9 WO2002055100A9 (en) 2006-05-11

Family

ID=26981351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051339 Ceased WO2002055100A2 (en) 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response

Country Status (8)

Country Link
EP (2) EP1333850B1 (en)
JP (2) JP2004537500A (en)
AT (1) ATE405282T1 (en)
AU (1) AU2002243443A1 (en)
DE (1) DE60135481D1 (en)
DK (1) DK1333850T3 (en)
ES (1) ES2311558T3 (en)
WO (1) WO2002055100A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
PL3718564T3 (en) * 2003-12-23 2024-03-18 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
US20050266005A1 (en) * 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
ES2523172T3 (en) * 2005-02-04 2014-11-21 Survac Aps Survivin Peptide Vaccine
JP2010502224A (en) 2006-09-08 2010-01-28 アボット・ラボラトリーズ Interleukin-13 binding protein
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
RU2578468C2 (en) 2010-12-16 2016-03-27 Дженентек, Инк. Methods for diagnosing and treating related to th2 inhibition
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (en) 2011-10-21 2014-07-14 Abbvie Inc. A combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV
CN120904322A (en) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (en) 2013-09-13 2017-10-18 Дженентек, Инк. COMPOSITIONS AND METHODS FOR DETECTING AND QUANTITATIVE DETERMINATION OF THE PROTEIN OF CELLS-OWNERS IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS
WO2015125652A1 (en) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 Therapeutic agent for solid cancer
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
TW202509218A (en) * 2023-07-12 2025-03-01 亨利傑克森軍方醫學基金會 Compositions and methods for the inhibition of natural killer cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
WO2000036103A1 (en) * 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
WO2000040264A1 (en) * 1999-01-07 2000-07-13 The Penn State Research Foundation Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US6143871A (en) * 1996-12-13 2000-11-07 Bonnefoy; Jean-Yves IL-13 and IL-4 binding polypeptides
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
EP1176140A1 (en) * 1999-02-10 2002-01-30 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH09150569A (en) 1995-11-29 1997-06-10 Riso Kagaku Corp Color image forming sheet
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US6143871A (en) * 1996-12-13 2000-11-07 Bonnefoy; Jean-Yves IL-13 and IL-4 binding polypeptides
WO2000036103A1 (en) * 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
WO2000040264A1 (en) * 1999-01-07 2000-07-13 The Penn State Research Foundation Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
EP1176140A1 (en) * 1999-02-10 2002-01-30 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors

Also Published As

Publication number Publication date
EP1333850A2 (en) 2003-08-13
JP2004537500A (en) 2004-12-16
DK1333850T3 (en) 2008-12-01
ATE405282T1 (en) 2008-09-15
WO2002055100A9 (en) 2006-05-11
AU2002243443A1 (en) 2002-07-24
EP1333850B1 (en) 2008-08-20
ES2311558T3 (en) 2009-02-16
JP2009046512A (en) 2009-03-05
AU2002243443A8 (en) 2005-10-13
EP2027867A1 (en) 2009-02-25
WO2002055100A2 (en) 2002-07-18
DE60135481D1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2002055100A3 (en) Method and composition for inhibition of tumor growth and enhancing an immune response
NZ524559A (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
YU28503A (en) Humanized anti-lt-betha-r antibodies
WO2004007679A3 (en) Dendritic cell pontentiation
IL164588A0 (en) ogenitor cells Novel methods for the invitro identification, isolation and differention of vasculogenic progenic pr
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
MXPA04005755A (en) Combination of cytochome p>450< dependent protease inhibitors.
MXPA03005659A (en) Method of improving yield and vigor of plants.
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
AU2001272951A1 (en) Coping with standoffs
ZA200106197B (en) Use of glycogen phosphorlase inhibitors to inhibit tumor growth.
WO2005001022A3 (en) Methods and compositions for enhancing immune response
AU2001264769A1 (en) Induction of apoptosis and cell growth inhibition by protein 4.33
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
WO2002067652A3 (en) Novel mutilple shoot proliferation and regeneration system for plants
AU2002239258A1 (en) Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
WO2002028433A3 (en) Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition
WO2002045704A3 (en) Prevention and treatment of tachyphylactic response
NZ524561A (en) 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
NZ524560A (en) 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inibitors
WO2002024227A1 (en) Tumor cell proliferation inhibitors
WO2001060351A3 (en) Nitroacridine/tumor inhibitor compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002555834

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001989341

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001989341

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGE 4, DESCRIPTION, REPLACED BY CORRECT PAGE 4